1700 patients (~900 patients receiving drug with the balance receiving placebo) evaluated to date in human healthy volunteers and five different indications including severe meningococcemia, hemorrhagic trauma, complicated abdominal infections, partial hepatectomy and cystic fibrosis. Two of these indications, meningococcemia and hemorrhagic trauma, have progressed to Phase III trials which are ongoing. Also, additional Neuprex ® indications are in planning. Because Neuprex ® has multiple clinically relevant properties, design of the clinical strategy has been a critical step in its development. An obvious clinical indication to have considered as part of this strategy, in spite of numerous failures by other biologicals, is all cause Gram-negative sepsis. In fact, sepsis was extensively reviewed and rejected as a lead indication in which to evaluate Neuprex ® . The reasons are manifold but may be best summarized by the clinical characteristics that we have actually used to select the current Neuprex ® indications:
• Homogenous patient population 21 , has been evaluated in over 1700 patients to date in human volunteer studies and five Phase I/II indications, involving patients with meningococcemia, hemorrhagic trauma, complicated abdominal infections, partial liver resections and cystic fibrosis. The product has demonstrated an excellent safety profile and evidence of biological activity in every study completed to date. Thus far, two indications, meningococcemia and hemorrhagic trauma, have moved into Phase III trials.
• Well-defined and accepted endpoints (available guidelines).
Aside from the last point (mortality being a welldefined and accepted endpoint), sepsis does not fit any of the clinical characteristics that have been incorporated into ongoing Neuprex ® trials. Such entry criteria result in a number of benefits. For example, the improved balance between treatment and placebo groups, resulting from more homogeneous populations, tends to decrease background noise, increase the probability of actually observing the drug's clinical benefit and possibly decrease the study population size. A known time of disease onset allows a more homogeneous timing for administration of study drug; in acute diseases this may be a critical variable. Also, if a disease has a predominant or single cause of death (e.g. as in meningococcemia), then comparison of drug versus placebo for all-cause mortality can be a strong measure of the drug's impact, since competition from other causes is not present. Particularly for acute diseases where multiple therapies may be administered simultaneously and variably, increasing homogeneity wherever possible is one of the important lessons to be learned from the multiple failed sepsis trials. 8 Thus, although preclinical data suggest that Neuprex ® should have clinical value in sepsis, we have selected an alternative clinical strategy.
With these thoughts in mind, Neuprex ® has demonstrated in the clinic to date an excellent safety profile and, equally important, evidence of biological activity in each clinical study completed to date. In Phase I studies, 172 healthy volunteers participated in a series of placebo-controlled trials from which no drug-related adverse events or immune responses to the protein were seen. Pharmacokinetics in volunteers receiving 30 min or 24 h infusions demonstrated that Neuprex ® has a circulating mean residence time of 8-35 min and predictable dose-dependent blood levels with primary clearance from the circulation through the liver (unpublished data, Bauer et al. 9 ). A randomized, doubleblinded, placebo-controlled endotoxin challenge trial in healthy volunteers demonstrated reduction in multiple endotoxin-induced parameters, relative to placebo. [10] [11] [12] The first disease in which Neuprex ® was evaluated was severe meningococcemia. Because of the non-specific early clinical features of this specific form of Gram-negative sepsis, patients, typically children, often present to physicians with a characteristic petechial rash in profound septic shock with no other underlying medical problems. 13 Although circulating Neisseria meningitidis is rapidly killed by conventional antibiotics, its endotoxin, a potent lipooligosaccharide (LOS), can achieve very high blood concentrations, resulting in continuation of shock and DIC even after the microorganism is no longer detectable. Treatment of meningococcemia constitutes a medical emergency because of the profound and rapid onset. And yet, in spite of major advances in critical care management, mortality rates have remained at 20-50% with at least 20% of survivors suffering gangrene with associated amputations/skin grafts or CNS complications such as strokes or seizures. Because no current therapy addresses the endotoxemia component of this disease and because Neuprex ® both neutralizes the LOS of N. meningitidis and is bactericidal to N. meningitidis, a clinical program was implemented to evaluate its adjunctive role in severe meningococcemia.
A Phase I/II, 26 patient, open label, dose-escalating trial has been completed in the US in 6 medical centers. 14 Children between 1 and 18 years with the diagnosis of presumed severe meningococcemia (Glasgow Meningococcal Septicemia Prognostic Score of [8] [9] [10] [11] [12] [13] [14] [15] , who could receive the study medication within 8 h of receiving antibiotics and were not at risk for imminent death, were eligible. Neuprex ® was given intravenously in three total doses of 1.0, 2.0 and 4.0 mg/kg. The total dose was divided equally between an initial 30 min infusion followed immediately with a 23.5 h continuous infusion (e.g. 4 mg/kg total dose = 2 mg/kg/30 min + 2 mg/kg/23.5 h). No drug related adverse events or other safety issues were noted. Endotoxemia at study entry was pronounced in this population with a median value of 371 pg/ml. Mortality in this study was 1 of 26 (4%) patients; a similar population who met the same entry criteria from the same enrolling centers during the two years prior to the start of this study had a mortality of 11 of 54 (20%) patients (Fig. 1) . Based on these and other supporting data and because of the rare and life threatening nature of this disease, the FDA granted this Neuprex ® indication Subpart E designation. This permitted initiation of a single pivotal randomized, double-blinded, placebo-controlled Phase III trial for licensure. This study, currently ongoing in the US and the UK, is designed to enroll approximately 300 patients and is scheduled to complete accrual in early 1999. Neuprex ® is also in advanced clinical testing in patients suffering hemorrhage due to trauma. Whereas the meningococcemia trial involves therapeutic intervention, the use of Neuprex ® in this trauma setting is prophylactic. Massive hemorrhage in the setting of trauma results in a number of complications, such as pneumonia and multiorgan failure, that often begin within the first 2-4 days after trauma. These may not be directly related to the event; rather, translocation of bacteria and endotoxin from the GI tract and secondary infections appear to be important contributing factors. 15, 16 The data supporting the use of Neuprex ® in this indication included several trauma animal models 17, 18 which led to a Phase II, 401 patient, randomized, double-blinded, placebo-controlled trial. 19 In this trial, trauma patients who received two or more units of blood and could receive Neuprex ® within 12 h of the trauma were eligible; isolated head trauma was an exclusion criterion. Patients received Neuprex ® (4 mg/kg/day) or placebo for 2 days by continuous infusion. This exploratory trial had a composite primary endpoint, evaluating a number of prospectively-defined infectious and organ-related complications. Of these, pulmonary complications (pneumonia and ARDS) were the most frequently observed endpoints in the placebo group (32%) and a 31% reduction seen in the Neuprex ® group (22%, P = 0.035). A second 169 patient Phase II trial has confirmed these observations (Fig. 2) . Based on these findings, Xoma has designed a single Phase III for licensure of this indication. This 1650 patient trial is currently ongoing in over 40 US centers with the goal of completing the trial by early 2000. Neuprex ® has also been evaluated in three other indications with small Phase II trials. These include patients with established complicated abdominal infections (CAI), cystic fibrosis and patients undergoing partial hepatectomy (PH). No safety issues have been seen in any of these trials. The results of the open-label, doseescalation 20 patient CAI trial demonstrated, in the primary endpoint, a dose-dependent numerical increase in patients who had a cure or improvement of their infectious complications. 19 The 12 patient low dose arm of the pilot randomized, placebo-controlled PH trial, which has been completed, demonstrated a numerical improvement in several clinical and laboratory parameters; 21 the 21 patient high dose arm of the trial has completed accrual and is undergoing analysis. The cystic fibrosis trial has completed accrual of the first arm of the trial and is also undergoing analysis. Finally, a number of other indications are under review and the overall clinical plan for Neuprex ® is to move at least one additional indication into advanced clinical development starting in 1999.
In conclusion, rBPI 21 has multiple anti-infective properties which, when combined with its safety profile and stability, encourage its evaluation, appropriately formulated, as systemic, topical and aerosol preparations in a wide range of diseases. While therapeutic intervention in a number of established diseases (e.g. meningococcemia) represents one potential clinical approach for Neuprex ® , the safety profile also permits evaluation for prophylactic use in high risk surgical settings. The increasing recognition that endotoxemia may play a pathogenic role in many non-Gram-negative infections and in a variety of (apparently) non-infectious diseases offers the potential for rBPI 21 to show therapeutic benefit in a number of unique clinical settings.
